The use of differential hybridization analysis to identify markers for diagnosis of urogenital cancerSCHALKEN, J. A.European urology. 1990, Vol 18, pp 52-57, issn 0302-2838, 6 p., suppl. 2Article

Les bases moléculaires de la progression tumorale dans le cancer de la prostate = The molecular basis of prostate cancer progressionSCHALKEN, J. A.Progrès en urologie. 1992, Vol 2, Num 4, pp 551-555Article

Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasiaSCHALKEN, J. A.BJU international. Supplement (Print). 2004, Vol 93, Num 1, pp 5-9, issn 1465-5101, 5 p.Article

A Targeted Approach to the Treatment of Advanced Prostate CancerABRAMS, P; SCHALKEN, J. A.BJU international. Supplement (Print). 2005, Vol 96, Num 2, issn 1465-5101, 56 p.Serial Issue

Therapeutic options in androgen-independent prostate cancer : building on docetaxelPETRYLAK, Daniel.BJU international. Supplement (Print). 2005, Vol 96, Num 2, pp 41-46, issn 1465-5101, 6 p.Article

Molecular prognostic factors in bladder cancerSCHALKEN, J. A.European urology. 1998, Vol 33, pp 13-14, issn 0302-2838, SUP4Conference Paper

Validation of molecular targets in prostate cancerSCHALKEN, Jack A.BJU international. Supplement (Print). 2005, Vol 96, Num 2, pp 23-29, issn 1465-5101, 7 p.Article

New perspectives in the treatment of prostate cancerSCHALKEN, J. A.European urology. 1997, Vol 31, pp 20-23, issn 0302-2838, SUP2Conference Paper

Molecular modelling of the androgen receptor axis : rational basis for androgen receptor intervention in androgen-independent prostate cancerFLETTERICK, Robert J.BJU international. Supplement (Print). 2005, Vol 96, Num 2, pp 2-9, issn 1465-5101, 8 p.Article

New strategies for the medical treatment of prostate cancerISAACS, John T.BJU international. Supplement (Print). 2005, Vol 96, Num 2, pp 35-40, issn 1465-5101, 6 p.Article

Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer : biological significance and clinical implicationsGIROLDI, L. A; SCHALKEN, J. A.Cancer metastasis reviews. 1993, Vol 12, Num 1, pp 29-37, issn 0167-7659Article

Functional genomics and transcriptomics of prostate cancer : promises and limitationsKALLIONIEMI, Olli.BJU international. Supplement (Print). 2005, Vol 96, Num 2, pp 10-15, issn 1465-5101, 6 p.Article

Identification of new prostate cancer progression markers by differential hybridization analysisSCHALKEN, J. A; DEBRUYNE, F. M. J.European urology. 1992, Vol 21, pp 60-65, issn 0302-2838, SUP1Conference Paper

Inflammation et hyperplasie bénigne de la prostate: cause ou conséquence? = Inflammation and benign prostatic hyperplasia: Cause or consequence?ROBERT, G; SALAGIERSKI, M; SCHALKEN, J. A et al.Progrès en urologie (Paris). 2010, Vol 20, Num 6, pp 402-407, issn 1166-7087, 6 p.Article

Changes in cadherin-catenin complexes in the progression of human bladder carcinomaGIROLDI, L. A; BRINGUIER, P.-P; SHIMAZUI, T et al.International journal of cancer. 1999, Vol 82, Num 1, pp 70-76, issn 0020-7136Article

Identification of intermediate cell types by keratin expression in the developing human prostateYONG XUE; SMEDTS, F; DEBRUYNE, F. M. J et al.The Prostate. 1998, Vol 34, Num 4, pp 292-301, issn 0270-4137Article

Loss of chromosome 9 in tissue sections of transitional cell carcinomas as detected by interphase cytogenetics. A comparison with RFLP analysisPODDIGHE, P. J; BRINGUIER, P.-P; VALLINGA, M et al.Journal of pathology. 1996, Vol 179, Num 2, pp 169-176, issn 0022-3417Article

p16 mutations/deletions are not frequent events in prostate cancerTAMIMI, Y; BRINGUIER, P. P; SMIT, F et al.British journal of cancer. 1996, Vol 74, Num 1, pp 120-122, issn 0007-0920Article

Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implicationsRUIJTER, E. T; VAN DE KAA, C. A; SCHALKEN, J. A et al.Journal of pathology. 1996, Vol 180, Num 3, pp 295-299, issn 0022-3417Article

Comparison of P53 protein overexpression with P53 mutation in bladder cancer : clinical and biologic aspectsVET, J. A. M; BRINGUIER, P. P; SCHAAFSMA, H. E et al.Laboratory investigation. 1995, Vol 73, Num 6, pp 837-843, issn 0023-6837Article

Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancerUMBAS, R; ISAACS, W. B; BRINGUIER, P. P et al.Cancer research (Baltimore). 1994, Vol 54, Num 14, pp 3929-3933, issn 0008-5472Article

Magnetic resonance spectroscopy detects metabolic differences between seven dunning rat prostate tumor sublines with different biological behaviorCORNEL, E. B; HEERSCHAP, A; SMITS, G. A. H. J et al.The Prostate. 1994, Vol 25, Num 1, pp 19-28, issn 0270-4137Article

p53 Mutations have no additional prognostic value over stage in bladder cancerVET, J. A. M; BRINGUIER, P. P; PODDIGHE, P. J et al.British journal of cancer. 1994, Vol 70, Num 3, pp 496-500, issn 0007-0920Article

Molecular prognostic factors in bladder cancerVET, J. A. M; DEBRUYNE, F. M. J; SCHALKEN, J. A et al.World journal of urology (Print). 1994, Vol 12, Num 2, pp 84-88, issn 0724-4983Article

Antitumor effects of bacillus Calmette-Guerin in a syngeneic rat bladder tumor model system, RBT323CORNEL, E. B; VAN MOORSELAAR, R. J. A; VAN STRATUM, P et al.The Journal of urology. 1993, Vol 149, Num 1, pp 179-182, issn 0022-5347Article